KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Cash & Equivalents (2017 - 2025)

Guardant Health (GH) has disclosed Cash & Equivalents for 9 consecutive years, with $378.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 28.04% to $378.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $378.2 million through Dec 2025, down 28.04% year-over-year, with the annual reading at $378.2 million for FY2025, 28.04% down from the prior year.
  • Cash & Equivalents hit $378.2 million in Q4 2025 for Guardant Health, down from $580.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.1 billion in Q4 2023 to a low of $141.6 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $583.3 million across 5 years, with a median of $576.8 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: plummeted 80.98% in 2022 and later skyrocketed 700.25% in 2023.
  • Year by year, Cash & Equivalents stood at $492.2 million in 2021, then plummeted by 71.22% to $141.6 million in 2022, then soared by 700.25% to $1.1 billion in 2023, then tumbled by 53.64% to $525.5 million in 2024, then decreased by 28.04% to $378.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for GH at $378.2 million in Q4 2025, $580.0 million in Q3 2025, and $629.1 million in Q2 2025.